Abstract
This book, one of four in a "Cancer Monograph Series" by British authors, summarizes data accumulated about the antimetabolites since their introduction by Farber in 1948. Dr. Timmis writes as a pioneer in cancer chemotherapy whose contributions include busulfan (Myleran), a chemical widely used in the treatment of chronic leukemia. One of the most challenging problems in chemotherapy has been the inevitable induction of resistance to antimetabolites with continued therapy. Presumably, alternate metabolic pathways develop which bypass the inhibitory effects of the drug. The search for methods to overcome resistance therefore requires understanding of the precise chemical action of these drugs and a knowledge of normal and possible alternate metabolic pathways. With this background,<i>Chemotherapy of Cancer</i>approaches its subject. The monograph is organized into six chapters each dealing with a major chemical group of antimetabolites. Chapters begin with an extensive, well-illustrated summary of the chemistry and pharmacology of the
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
